LFCR Q3 2021 Earnings — Lifecore Biomedical, Inc. Revenue & Financial Results | Market Cap Arena

LFCRLifecore Biomedical, Inc.

$256M

Q3 2021 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$45M-70.8% YoY

Gross Profit

$14M32.3% margin

Operating Income

$2M5.5% margin

Net Income

-$5M-12.3% margin

EPS (Diluted)

$-0.19

QoQ Revenue Growth

-65.9%

Cash Flow

Operating Cash Flow

-$8M

Free Cash Flow

-$12M

Stock-Based Comp.

$797,000

Balance Sheet

Total Assets

$510M

Total Liabilities

$305M

Stockholders' Equity

$205M

Cash & Equivalents

$2M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$45M	$153M	-70.8%
Gross Profit	$14M	$20M	-28.0%
Operating Income	$2M	-$15M	+116.3%
Net Income	-$5M	-$12M	+52.3%